FDA broadens label for Amgen's Uplizna as it enters rare disease competition

The FDA on Thursday expanded the label for Amgen’s rare disease drug Uplizna, approving it in an autoimmune disorder that’s quickly become a hot — and crowded — area for biopharma. Regulators gave the green light to ...